

BioGeneric Pharma S.A.E.



Overview

BioGeneric Pharma "BGP" is an Egyptian private company with multi-national shareholders:

- > Egypt:
 - Egyptian Private Investors
 - Pharco Corporation "Ranked No. 1 in 2022"
- > Saudi Arabia:
 - Saudi Private Investors
- > China:
 - Amotyop Biotech Company "Listed in the Stock Market"
- > USA:
 - BioGeneric Ltd.

BGP has a newly-established state-of-the-art biopharmaceutical facility specialized in manufacturing of:

- > Therapeutic recombinant proteins
- > Preventive vaccines

Its main principle activities:

- ➤ R&D
- ➤ Bio-production
- Analysis
- Commercialization



BGP Production Capabilities



Drug Substance Production Facility:

- Mixers (50 L to 1500 L)
- Tissue culture flasks up to 2000 ml
- Bioreactors from 25 L to 2000 L
- Clarification systems with depth filters up to 20 m²
- Single-use dual chromatography/TFF systems up to 3600 L/h
- Systems for the final drug substance filtration up to 2.0 m²
 All equipment operate via single use technology

BSL+2 Quality Control Labs:

- All lab activities are managed by electronic LIMS, ensuring data integrity and audit trails according to CFR- 21 Part 11
- Integrated with electronic QMS & Oracle system managing production & warehouses

BGP Production Capabilities



Formulation & Filling Facilities:

1. Robotic Line (Vial, Cartridges and Pre-filled syringes):

Container	Annual Capacity
PFS	30,144,000
Cartridge	21,888,000
6R Vial	16,128,000
20R Vial	8,480,000
50R Vial	4,480,000

2. Conventional Vial Line:

Container	Annual Capacity
2R Vial	76,800,000
6R Vial	64,000,000
10R Vial	55,296,000
20R Vial	32,832,000
50R Vial	12,288,000



BGP's Portfolio



1 vial of powder for

concentrate for solution

for I.V. infusion

Dose & administration

Ser radiace insert.

Smallet


Potest from light

Constituent - Donat state

Kespoutofreath of children

بظفر يخاونها الرايضية

150





For LV, use after diution Rituxigen 100 mg/ Each vial contains: Rituinab 100 mg Excipients: Sodium citate dhydrate, Rituximab Polysottate RD, Sodium chloride, Hydrodiloric acid q.s. pH 6.5, Water for injection. Dose & administration: 2 vials of 10 ml of See package insert. Store at 2.8 °C concentrate for solution Protect from light for infusion Do not freeze - Do not shake Keep out of reach of children.

البعد-البن مطعباء بنار الفعار

بطعبا تراعو





10 ml

Rituximab



1 vial of 50 ml of concentrate for solution for infusion

Rituxigen 500 mg/





Each vial contains

Trastuzumab 440 mg

Excipients: Historie hydrochloride

Monohydrate.

Trehalose dihydrate, Polysorbate 20.

Berzovi alcohol

Water for injection

Dose & administration:

Do not freeze - Do not stake Keep out of reach of children.

See package insert. Store at 2-8 °C

Protect from light

Each solvent vial contains

Historie

TrastuThera 440 mg Trastuzumab 440 mg

1 multi-dose vial powder for

concentrate for solution for I.V. infusion 1 vial of 20 ml bacteriostatic WFI









BGP and Partners

BGP

What does BGP offer?

- CMO/CDMO activities
- > Toll Manufacturing
- Out-licensing
- > Training
- Upskilling

What is BGP looking for?

- > Technology Transfer
- Partnerships
- > Financial Projects
- > R&D Collaboration
- ➤ Joint-venture Projects

